

FIG. 1




FIG. 2




FIG. 3





FIG. 4






FIG. 5




FIG. 7




FIG. 6




FIG. 8




FIG. 9










FIG. 10



4/21




5/21



6/21

FIG. 17FIG. 18


7/21

FIG. 19




8/21

PROFIL DE LIBERATION IN VIVO DES INSERTS DE  
DEXAMETHASONE (10 %) ADMINISTRE CHEZ LE  
RAT EN SOUS-CUTANE.



FIG. 20A

PROFIL DE LIBERATION IN VIVO DES INSERTS DE  
DEXAMETHASONE (15 %) ADMINISTRE CHEZ LE  
RAT EN INTRA-PERITONEAL.

FIG. 20B




9/21


FIG. 21AFIG. 21B

10/21

PROFIL DE LIBERATION DES INSERTS DE  
DEXAMETHASONE (20 %) ADMINISTRE CHEZ LE  
RAT EN SOUS-CUTANE.


FIG. 22A

PROFIL DE LIBERATION DES INSERTS DE  
DEXAMETHASONE (20 %) ADMINISTRE CHEZ LE  
RAT EN INTRA-PERITONEAL.



FIG. 22B

11/21

ETUDE PHARMACOCINETIQUE SUR LE CHIEN DE 12,8 mg DE  
LA FORME SOLIDE DE L'ACETATE DE LANREOTIDE INJECTEE EN  
INTRAMUSCULAIRE.

FIG. 23

12/21



13/21

CONCENTRATION DE LANREOTIDE DANS LE SANG DE VOLONTAIRES  
SAINS APRES UNE INJECTION INTRAMUSCULAIRE DE 40 mg DE  
LANREOTIDE SOUS FORME SEMI-SOLIDE.








FIG. 25

14/21

FIG. 26FIG.27


15/21

FIG. 28FIG. 29




16/21

FIG.30






t-0,1h,1j,2j,3j,7j,10j



t-0,1h,1j,2j,3j,7j,10j

FIG.31



FIG. 32FIG. 33

18/21




FIG. 34








FIG. 35

19/21

FIG. 36FIG. 37

20/21



21/21




FIG.39